Hutchmed sells its 45% stake in SHPL for $608 million, aligning with its focus on oncology and immunology. Proceeds will fund ...

Kazia Therapeutics faces a setback as the FDA deems accelerated approval for brain cancer drug paxalisib unlikely despite ...

California-based IDEAYA Biosciences has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo ...

The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) ...

Austrian arenaviral technology firm HOOKIPA Pharma and Poolbeg Pharma have entered into non-binding discussions for an ...

Pfizer ends its collaboration with Sangamo Therapeutics on a haemophilia A gene therapy despite strong Phase III results and ...

The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under the accelerated ...

The new $2,000 cap on out-of-pocket costs for prescription drugs went into effect as of January 1, 2025, the US Department of ...

The AI in cancer care market is set to grow from $2.2 billion in 2024 to $6.3 billion by 2029, driven by advancements in drug ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Imdyllytra (tarlatamab) for the ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Winrevair (sotatercept) to treat pulmonary ...

US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 ...